ANAPTYSBIO, INC - 8-K Filing
AnaptysBio reported first-quarter revenue of $25.6 million from collaboration royalties in Q1 2026, a decrease from $27.8 million in the same period last year due to one-time Vanda license agreement income recognized in Q1 2025 being offset by higher Jemperli royalty growth (up 44% YoY). The company reported a net loss of $52.9 million, or $1.84 per share for the quarter ended March 31, 2026, compared to a net loss of $39.3 million ($1.28/share) in Q1 2025. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $ANAB